{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T05:59:41Z","timestamp":1778997581945,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejpb.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:48:32Z","timestamp":1634604512000},"page":"200-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: Rapid distribution throughout the posterior segment"],"prefix":"10.1016","volume":"169","author":[{"given":"Ifat","family":"Sher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehavit","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettel","family":"Bubis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoreh","family":"Barak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ygal","family":"Rotenstreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpb.2021.10.003_b0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"4-5","key":"10.1016\/j.ejpb.2021.10.003_b0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10792-007-9036-y","article-title":"Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab","volume":"26","author":"Ahmadieh","year":"2007","journal-title":"Int. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2021.10.003_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"10.1016\/j.ejpb.2021.10.003_b0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/IJG.0000000000000241","article-title":"Clinical Outcomes of Ahmed Glaucoma Valve Implantation With or Without Intravitreal Bevacizumab Pretreatment for Neovascular Glaucoma: A Systematic Review and Meta-Analysis","volume":"25","author":"Zhou","year":"2016","journal-title":"J. Glaucoma"},{"issue":"3","key":"10.1016\/j.ejpb.2021.10.003_b0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/1120672119827773","article-title":"The use of bevacizumab in pediatric retinal and choroidal disease: A review","volume":"29","author":"Belin","year":"2019","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.10.003_b0030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4103\/0301-4738.154380","article-title":"Choroidal metastases: origin, features, and therapy","volume":"63","author":"Arepalli","year":"2015","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.10.003_b0035","doi-asserted-by":"crossref","unstructured":"M.D. McLaughlin, J.C. Hwang, Trends in vitreoretinal procedures for medicare beneficiaries, 2000 to 2014., Ophthalmology. 124 (2017) 667\u2013673. doi:10.1016\/j.ophtha.2017.01.001.","DOI":"10.1016\/j.ophtha.2017.01.001"},{"key":"10.1016\/j.ejpb.2021.10.003_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2021.03.003","article-title":"Utilization of bevacizumab injections in medicare fee for service in the IRIS\u00ae registry","author":"Repka","year":"2021","journal-title":"Ophthalmol. Retina."},{"key":"10.1016\/j.ejpb.2021.10.003_b0045","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, S.L. Fine, G. Ying, G.J. Jaffe, et al., Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results., Ophthalmology. 119 (2012) 1388\u20131398. doi:10.1016\/j.ophtha.2012.03.053.","DOI":"10.1016\/j.ophtha.2012.03.053"},{"issue":"1","key":"10.1016\/j.ejpb.2021.10.003_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ejpb.2021.10.003_b0055","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.ejpb.2021.10.003_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5693\/djo.01.2014.07.001","article-title":"Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports","volume":"21","author":"Karabag","year":"2015","journal-title":"Digit. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.10.003_b0065","doi-asserted-by":"crossref","unstructured":"C.H. Meyer, S. Michels, E.B. Rodrigues, A. Hager, S. Mennel, J.C. Schmidt, et al., Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections., Acta Ophthalmol. 89 (2011) 70\u201375. doi:10.1111\/j.1755-3768.2010.02064.x.","DOI":"10.1111\/j.1755-3768.2010.02064.x"},{"key":"10.1016\/j.ejpb.2021.10.003_b0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/OPTH.S4641","article-title":"Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia","volume":"3","author":"Brouzas","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.10.003_b0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000213644","article-title":"Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab","volume":"223","author":"Karagiannis","year":"2009","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.ejpb.2021.10.003_b0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.eye.6702938","article-title":"Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab","volume":"23","author":"Bakri","year":"2009","journal-title":"Eye (Lond.)"},{"issue":"5","key":"10.1016\/j.ejpb.2021.10.003_b0085","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ejpb.2021.10.003_b0090","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.10.003_b0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/IAE.0b013e31819a5f98","article-title":"Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections","volume":"29","author":"Ladas","year":"2009","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"4","key":"10.1016\/j.ejpb.2021.10.003_b0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","article-title":"The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology","volume":"126","author":"Hoguet","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ejpb.2021.10.003_b0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv. Ophthalmol."},{"issue":"9","key":"10.1016\/j.ejpb.2021.10.003_b0110","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/02713683.2021.1874023","article-title":"Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period","volume":"46","author":"Pancholy","year":"2021","journal-title":"Curr. Eye Res."},{"issue":"8","key":"10.1016\/j.ejpb.2021.10.003_b0115","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ophtha.2018.01.022","article-title":"Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes","volume":"125","author":"Xu","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2021.10.003_b0120","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model","volume":"52","author":"Olsen","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2021.10.003_b0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1167\/iovs.07-1225","article-title":"Subretinal bevacizumab detection after intravitreous injection in rabbits","volume":"49","author":"Dib","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2021.10.003_b0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","article-title":"Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment","volume":"133","author":"Bressler","year":"2015","journal-title":"JAMA Ophthalmol."},{"issue":"8","key":"10.1016\/j.ejpb.2021.10.003_b0135","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","article-title":"Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model","volume":"14","author":"Hutton-Smith","year":"2017","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2021.10.003_b0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/eye.2015.21","article-title":"Failure of intravitreal bevacizumab in the treatment of choroidal metastasis","volume":"29","author":"Maudgil","year":"2015","journal-title":"Eye (Lond.)"},{"issue":"1","key":"10.1016\/j.ejpb.2021.10.003_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0438-y","article-title":"In vivo MRI assessment of bioactive magnetic iron oxide\/human serum albumin nanoparticle delivery into the posterior segment of the eye in a rat model of retinal degeneration","volume":"17","author":"Tzameret","year":"2019","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.ejpb.2021.10.003_b0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.exer.2013.10.023","article-title":"Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy","volume":"118","author":"Tzameret","year":"2014","journal-title":"Exp. Eye Res."},{"issue":"3","key":"10.1016\/j.ejpb.2021.10.003_b0155","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1111\/aos.13238","article-title":"A minimally invasive adjustable-depth blunt injector for delivery of pharmaceuticals into the posterior pole","volume":"95","author":"Rotenstreich","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2021.10.003_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/4061975","article-title":"Long-Term Safety of Transplanting Human Bone Marrow Stromal Cells into the Extravascular Spaces of the Choroid of Rabbits","author":"Tzameret","year":"2017","journal-title":"Stem Cells Int."},{"issue":"11","key":"10.1016\/j.ejpb.2021.10.003_b0165","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s10792-020-01471-9","article-title":"Efficacy and safety of injecting increasing volumes into the extravascular spaces of the choroid using a blunt adjustable depth injector","volume":"40","author":"Sher","year":"2020","journal-title":"Int. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.10.003_b0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jtos.2019.09.009","article-title":"Repetitive magnetic stimulation protects corneal epithelium in a rabbit model of short-term exposure keratopathy","volume":"18","author":"Sher","year":"2020","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejpb.2021.10.003_b0175","unstructured":"Protocol: PK Bridging ELISA for use with Anti-bevacizumab Antibody, (n.d.). https:\/\/www.bio-rad-antibodies.com\/protocol-pk-bridging-elisa-bevacizumab-antibodies.html (accessed March 1, 2021)."},{"issue":"4","key":"10.1016\/j.ejpb.2021.10.003_b0180","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"issue":"10","key":"10.1016\/j.ejpb.2021.10.003_b0185","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2021.10.003_b0190","article-title":"Pharmacokinetics and Biodistribution of Bevacizumab Following Suprachoroidal Injection into the Rabbit Eye Using a Microneedle","author":"Mansoor","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2021.10.003_b0195","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2021.10.003_b0200","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis","year":"2011","journal-title":"Clin Ophthalmol."},{"issue":"3","key":"10.1016\/j.ejpb.2021.10.003_b0205","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"7","key":"10.1016\/j.ejpb.2021.10.003_b0210","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/jop.2013.0009","article-title":"Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes","volume":"29","author":"Ahn","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.10.003_b0215","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0b013e3180592ba6","article-title":"Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin)","volume":"27","author":"Falkenstein","year":"2007","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"4","key":"10.1016\/j.ejpb.2021.10.003_b0220","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","article-title":"Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes","volume":"48","author":"Inan","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:46:28Z","timestamp":1760546788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121002587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"alternative-id":["S0939641121002587"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.10.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: Rapid distribution throughout the posterior segment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}